Oncoematologia
Diasorin
IAM – LIASON
IAM BCR-ABL Kit (Qualitative)
An ultra rapid molecular solution for one-step differential detection of BCR-ABL common and rare fusion transcripts.
The BCR-ABL fusion gene codes for an oncogenic protein with elevated tyrosine kinase activity, which is responsible for the neoplastic transformation. The timely and accurate molecular detection of the BCR-ABL transcripts is mandatory in order to diagnose Philadelphia Positive Leukemias allowing implementation of targeted therapies, which are able to selectively inactivate the BCR-ABL chimeric protein.
IAM PML-RARA Kit
An ultra rapid molecular solution for one-step differential detection of BCR-ABL common and rare fusion transcripts.
The BCR-ABL fusion gene codes for an oncogenic protein with elevated tyrosine kinase activity, which is responsible for the neoplastic transformation. The timely and accurate molecular detection of the BCR-ABL transcripts is mandatory in order to diagnose Philadelphia Positive Leukemias allowing implementation of targeted therapies, which are able to selectively inactivate the BCR-ABL chimeric protein.
IAM AML1-ETO Kit
AML1-ETO/t (8;21)(q22;q22)/ RUNX1-RUNX1T1 is a recurrent genetic abnormality in both childhood and adult Acute Myeloid Leukemia (5-10% of all AML and nearly 40% of the AML FAB M2 subtype). Although this translocation is associated with a good prognosis, only 50% of patients are cured and its rapid molecular identification is crucial for risk stratification of patients and therapeutic decisions.
IAM CBFB_MYH11 Kit
CBFB-MYH11, also known as PEBP2B-MYH11, inv(16), t(16;16) is a recurrent genetic abnormality especially in adult Acute Myeloid Leukemia (10% of all de novo AML). This translocation is also one of the most frequently balanced chromosomal translocations found in patients with therapy-related AML (t-AML). Although this genetic alteration is associated with a good prognosis, 30%-40% of these patients experience relapse and its rapid molecular identification is considered crucial for patients’ management and therapeutic decisions.